Skip to main content Skip to section navigation Skip to footer
Immunovant, Inc.
  • Home
  • About Us
  • Pipeline
    • Mechanism of Action
    • Indications
  • For Investors
    • Overview
    • Immunovant R&D Day
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Join Us
    • Our Benefits
    • Our Careers
  • Contact Us

Press Releases

For Investors

For Investors

  • Overview
  • Immunovant R&D Day
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
May 23, 2022 4:05pm EDT

Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th

May 19, 2022 4:05pm EDT

Immunovant to Present at the UBS Global Healthcare Conference on May 23rd

May 04, 2022 8:00am EDT

Immunovant to Present at LifeSci Partners’ Immunology and Inflammation Symposium on May 10th

Mar 28, 2022 7:00am EDT

Immunovant to Host Virtual R&D Day on March 30, 2022

Feb 09, 2022 8:00am EST

Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Feb 04, 2022 7:00am EST

Immunovant Reports Financial Results for the Quarter Ended December 31, 2021

Jan 25, 2022 8:30am EST

Immunovant Appoints Mark Levine as Chief Legal Officer

Jan 07, 2022 2:07pm EST

Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference

Dec 30, 2021 7:00am EST

Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

Nov 12, 2021 12:18pm EST

Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

  • 1
  • 2
  • 3
  • 4
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2022 Immunovant, Inc. All Rights Reserved.
Privacy Policy Terms of Use Disclaimer Sitemap